Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic systemic inflammatory arthritis that affects 0.8% of the UK population. Objectives: To determine whether or not an alternative class of biologic disease-modifying antirheumatic drugs (bDMARDs) are compa...

Full description

Bibliographic Details
Main Authors: Sarah Brown, Colin C Everett, Kamran Naraghi, Claire Davies, Bryony Dawkins, Claire Hulme, Christopher McCabe, Sue Pavitt, Paul Emery, Linda Sharples, Maya H Buch
Format: Article
Language:English
Published: NIHR Journals Library 2018-06-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta22340

Internet

https://doi.org/10.3310/hta22340

Similar Items